Silence Therapeutics shares are trading higher after BMO Capital initiated coverage on the stock with an Outperform rating and $67 price target.
Portfolio Pulse from Benzinga Newsdesk
Silence Therapeutics' stock price has risen following BMO Capital's initiation of coverage with an Outperform rating and a $67 price target.
January 31, 2024 | 3:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Silence Therapeutics' stock is likely to experience a positive short term impact due to BMO Capital's Outperform rating and $67 price target.
Analyst ratings, especially from reputable firms like BMO Capital, can significantly influence investor sentiment and stock prices. The Outperform rating and ambitious price target suggest a strong positive outlook for Silence Therapeutics, which can lead to increased investor interest and a rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100